Thermo Fisher Scientific will unveil the Cellomics Comet v3.0 Bio-application at the SOT 48th Annual Meeting and ToxExpo, Baltimore, Maryland, on 15-19 March.
This application uses a cell-based imaging approach for addressing the bottleneck of rapid and accurate DNA damage assessment based on the Comet assay.
This assay, also known as single cell gel electrophoresis (SCGE) is a commonly used assay to ascertain DNA damage induced in cells by acute exposure to chemicals or radiation.
The Comet Bio-application runs on the Thermo Scientific Cellomics Arrayscan VTI system (comprising instrumentation, informatics and reagent products) and provides automatic acquisition and quantification of Comet assays.
Researchers are now able to rapidly test multiple compounds for the potential effects of DNA damage offering a more productive method for screening compounds earlier in the drug-discovery process.
In addition, the Comet Bio-application provides a more reproducible method for compound screening at lower labour costs compared with traditional manual approaches to Comet quantification.
The Comet Bio-application for use on the Thermo Scientific Arrayscan VTI HCS Reader is a completely automated tool for acquiring and analysing Comet assays to assess DNA damage in studies related to genotoxicity, ecotoxicity, and biomonitoring.
With the launch of the Cellomics Comet v3.0 Bio-application, more tests may be performed with an industry standard assay configuration.
This automated, quantitative high-content approach enables screening for indicators of genetic toxicity earlier in the development of therapeutic candidates and is designed to improve attrition rates, increasing efficiency and reducing costs for pharmaceutical companies.
